Presentation
A detailed time course of anti-A titers, plasma cell content of the marrow, and B-cell content of the blood is presented. [ncbi.nlm.nih.gov]
Our case presentation, we present a case of bortezomib-induced biopsy-proven AIN, which, to our knowledge, has not previously been reported. [doi.org]
Entire Body System
-
Intravenous Administration
Characterize bortezomib pharmacokinetics/pharmacodynamics in relapsed myeloma patients after single and repeat intravenous administration at two doses. [ncbi.nlm.nih.gov]
Keith Stewart Original Article First Online: 20 March 2010 Abstract Purpose Characterize bortezomib pharmacokinetics/pharmacodynamics in relapsed myeloma patients after single and repeat intravenous administration at two doses. [doi.org]
"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study". The Lancet Oncology. 12 (5): 431–40. doi : 10.1016/s1470-2045(11)70081-x. PMID 21507715. [en.wikipedia.org]
[see How Supplied/Storage and Handling] In clinical trials, local skin irritation was reported in 5% of patients, but extravasation of VELCADE was not associated with tissue damage. 2.7 Reconstitution/Preparation for Intravenous Administration Proper [globalrph.com]
-
Hyperthermia
KEYWORDS: Apoptosis; Blood cancer; Bortezomib; Cytotoxicity; Hyperthermia; Velcade [ncbi.nlm.nih.gov]
-
Hypoxemia
This report describes a 57-year-old patient with light chain (primary) amyloidosis receiving weekly subcutaneous bortezomib injections who presented with recurrent hypoxemia and interstitial pneumonitis. [ncbi.nlm.nih.gov]
-
Turkish
M Beksac, R Haznedar, T Firatli-Tuglular, etal: Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: Results of a randomized trial from the Turkish Myeloma Study Group Eur J Haematol [doi.org]
Neurologic
-
Peripheral Neuropathy
Four patients who developed a bortezomib-induced peripheral neuropathy underwent electrophysiological testing, and 1 patient had a nerve biopsy. [ncbi.nlm.nih.gov]
Neuropathy Risk of severe (grade 3 or greater) new-onset peripheral neuropathy or exacerbation of preexisting peripheral neuropathy. 1 Occurs predominantly as peripheral sensory neuropathy, but severe peripheral motor neuropathy also reported. 1 Manifestations [drugs.com]
Peripheral neuropathy Severe sensory and motor peripheral neuropathy has been reported with bortezomib use. [pdr.net]
-
Altered Mental Status
Posterior reversible encephalopathy syndrome (PRES) is a neuroradiological syndrome characterised by vasogenic oedema involving the postero-occipital cortical and subcortical white matter resulting in visual disturbances, seizures and altered mental status [ncbi.nlm.nih.gov]
Workup
Serum
-
Philadelphia Chromosome Positive
We investigated in vitro BTZ sensitivity in a large panel of ALL cell lines that acted as a model system for refractory ALL, and found that Philadelphia chromosome-positive (Ph ) ALL, IKZF1 deletion, and biallelic loss of CDKN2A were associated with favorable [ncbi.nlm.nih.gov]
Biopsy
-
Liver Biopsy
A liver biopsy showed light chain deposition in Disse spaces. [ncbi.nlm.nih.gov]
Treatment
We conclude that bortezomib could be an attractive escalating treatment option with a good side-effect profile for patients with treatment refractory CIDP. [ncbi.nlm.nih.gov]
Prognosis
However, isolated CNS relapse is even less common; an event which carries a very poor prognosis. [ncbi.nlm.nih.gov]
Epidemiology
Surveillance, Epidemiology, and End Results Program. 2016. Available at . Accessed December 13, 2016. 3. Multiple myeloma drug therapies. The MMRF. 2016. Available at . Accessed December 13, 2016. 4. Neumann PJ, Cohen JT, Weinstein MC. [amgen.com]
Universitätsmedizin Berlin, Berlin, Germany 2 Department of Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany 3 Neurocure Clincal Research Center, Charite Universitätsmedizin Berlin, Berlin, Germany 4 Institute of Biometry and Clinical Epidemiology [bmjopen.bmj.com]
Another important issue is the risk of developing second primary malignancies because patients are living longer from time of diagnosis. 21 Population studies 22 – 25 and data from the National Cancer Institute's Surveillance, Epidemiology, and End Results [doi.org]
The eGFR was calculated according to the chronic kidney disease epidemiology collaboration formula. 11 Adherence to immunosuppressive medication was evaluated by self-assessment of all 19 patients alive. [journals.lww.com]
The study was investigated in accordance with the ethical principles stated in the most recent version of the Declaration of Helsinki or the applicable guidelines on epidemiological studies issued by the Ministry of Health, Labor and Welfare and the Ministry [bmccancer.biomedcentral.com]
Pathophysiology
The incidence of severe adverse effects in clinical trials was lower than 5%, and severe pulmonary complications were not described before the publication of a series of 4 cases. 1 The pathophysiological mechanism of bortezomib lung injury is not well [archbronconeumol.org]
Introduction In spite of a diversity of clinical manifestations, a number of autoimmune diseases are characterised by a common pathophysiology with the production of pathogenic autoantibodies leading to an autoimmune attack on various body sites such [bmjopen.bmj.com]
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001 ;20: 4519 - 4527 15. Hideshima T, Chauhan D, Richardson P, et al. [nejm.org]
Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J Hematol Oncol. 2017;10:67. . [jhoonline.biomedcentral.com]
The pathophysiology of POEMS syndrome is not well understood, but it may be related to changes in the levels of a cytokine or an overproduction of vascular endothelial growth factor (VEGF), probably secreted by clonal plasma cells. [medicalpolicies.amerigroup.com]
Prevention
Taken together, these results suggest the possibility of developing novel antihypertensive drugs that prevent CYP11B2 expression. Copyright 2017 Elsevier Inc. All rights reserved. [ncbi.nlm.nih.gov]